Actos (Pioglitazone) Cost in Missouri: 2026 Prices, Insurance, and Savings

What Generic Pioglitazone Costs at Missouri Pharmacies in 2026

A 30-day supply of generic pioglitazone 30 mg averages roughly $15 at Missouri retail pharmacies in 2026, making it one of the least expensive branded-to-generic diabetes medications on the market. Brand-name Actos from Takeda carries a manufacturer list price near $60 per month, but very few patients pay that figure because generics dominate dispensing.

Pioglitazone lost patent exclusivity in 2012, and multiple generic manufacturers now compete for market share. That competition has compressed retail pricing across all 50 states, Missouri included. Pharmacies in the St. Louis and Kansas City metro areas tend to cluster near the $12 to $18 range for a 30-day supply, while rural pharmacies may charge slightly more due to lower dispensing volume. Warehouse clubs like Costco and Sam's Club often stock pioglitazone on $4-to-$10 generic lists, though membership may be required for pharmacy access in some locations.

Cash-pay patients should always request a price check at multiple pharmacies. Missouri has no state law capping prescription drug prices, so variation between chains and independents is common. GoodRx, RxSaver, and similar discount aggregators can surface real-time pricing at nearby pharmacies, sometimes pulling the effective cost below $10 for a 30-day supply [1].

The 45 mg strength typically costs $1 to $3 more per month than the 30 mg tablet. Prescribers sometimes start patients at 15 mg and titrate upward, so initial fills may be even cheaper. The FDA-approved prescribing information for pioglitazone lists 15 mg, 30 mg, and 45 mg as the available strengths, each dosed once daily [2].

Missouri Medicaid Coverage for Pioglitazone

Missouri Medicaid (MO HealthNet) covers pioglitazone for its FDA-approved indication of type 2 diabetes mellitus. Off-label use for nonalcoholic steatohepatitis (NASH) is not a covered indication under the current MO HealthNet preferred drug list, even though clinical trial data supports that use.

MO HealthNet operates a preferred drug list (PDL) that categorizes medications by therapeutic class. Generic pioglitazone sits on the PDL as a preferred thiazolidinedione for type 2 diabetes, meaning most enrollees can fill it without prior authorization. Brand-name Actos, by contrast, typically requires a prior authorization demonstrating that the generic is unavailable or clinically inappropriate.

For patients who need pioglitazone for NASH (now formally called metabolic dysfunction-associated steatohepatitis, or MASH), coverage denial is the expected outcome. The PIVENS trial (N=247) published in the New England Journal of Medicine demonstrated that pioglitazone 30 mg produced significant histological improvement in NASH patients compared with placebo, with 34% of pioglitazone-treated patients achieving resolution of steatohepatitis versus 19% on placebo [3]. Despite this evidence, Missouri Medicaid has not extended formulary coverage to the NASH indication.

Enrollees who receive a denial can file a fair hearing request through the Missouri Department of Social Services. "Thiazolidinediones remain the best-studied pharmacotherapy for NASH, and pioglitazone's benefit on liver histology is well-documented," notes the 2023 AACE Clinical Practice Guideline for NAFLD [4]. Attaching guideline citations and hepatology notes to an appeal strengthens the case, though approval rates for off-label NASH coverage remain low across most state Medicaid programs.

How Insurance Plans Handle Pioglitazone in Missouri

Most commercial insurance plans in Missouri place generic pioglitazone on Tier 1 (preferred generics), resulting in copays between $0 and $15 per month. Brand-name Actos, when covered at all, usually falls on Tier 3 or higher with copays of $40 to $75.

Blue Cross Blue Shield of Kansas City, Anthem Blue Cross (Wellpoint), and Cigna all list generic pioglitazone as a preferred agent in their 2026 Missouri formularies. UnitedHealthcare and Aetna similarly classify it as Tier 1. Patients enrolled in Medicare Part D plans will find pioglitazone in the generic tier with typical copays of $0 to $10, and after the Inflation Reduction Act's $2,000 annual out-of-pocket cap took full effect in 2025, even patients taking multiple diabetes medications face a hard ceiling on total yearly drug spending [5].

High-deductible health plans present the main exception. Patients on HDHPs must meet their deductible before insurance pricing kicks in, which means they pay full cash price until that threshold is reached. For a $15-per-month generic, the financial impact is modest, but patients stacking pioglitazone with GLP-1 receptor agonists or SGLT2 inhibitors may cross that deductible quickly.

Employer-sponsored plans in Missouri occasionally exclude thiazolidinediones entirely, routing patients toward metformin or DPP-4 inhibitors as first-line options. A formulary exception request from the prescribing physician, supported by documentation of metformin intolerance or contraindication, usually resolves these blocks within 5 to 10 business days.

Compounded Pioglitazone in Missouri: Legality and Access

Compounded pioglitazone is legal in Missouri when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Missouri follows federal Drug Quality and Security Act (DQSA) guidelines, which permit 503A pharmacies to compound medications that are not commercially available in the needed form or strength.

503A pharmacies in Missouri must hold a current Missouri Board of Pharmacy license and comply with USP <795> standards for nonsterile compounding. Pioglitazone compounding most commonly serves patients who need a dose not available in commercial tablets (for example, 7.5 mg or 22.5 mg for dose titration), patients who cannot swallow tablets and need a suspension, or pediatric patients requiring weight-based dosing.

The cost of compounded pioglitazone varies by pharmacy and formulation. Some 503A pharmacies offer compounded pioglitazone at minimal or no additional cost above the raw ingredient price, particularly when the active pharmaceutical ingredient (API) is inexpensive. Given that commercial generic pioglitazone already costs around $15 per month, compounding is rarely pursued for cost savings alone. The primary driver is formulation flexibility.

503B outsourcing facilities, which can compound without patient-specific prescriptions, also operate in Missouri. These facilities fall under stricter FDA oversight and must register with the agency, report adverse events, and comply with current good manufacturing practice (cGMP) requirements. Patients should verify that any compounding pharmacy they use holds appropriate state and federal registrations through the Missouri Board of Pharmacy license verification portal.

Telehealth Prescribing of Pioglitazone in Missouri

Missouri permits telehealth prescribing of pioglitazone without geographic or originating-site restrictions, meaning patients anywhere in the state can receive a prescription through a video or audio visit with a licensed prescriber. This became permanent after Missouri updated its telehealth statutes (RSMo §191.1145 and §334.108) following the COVID-era temporary expansions.

A prescriber must hold an active Missouri medical license or practice under the Interstate Medical Licensure Compact, which Missouri joined. The prescriber must establish a valid physician-patient relationship, which Missouri law allows via synchronous audiovisual technology. Audio-only visits are also permitted for established patients, though initial evaluations typically require video.

For pioglitazone specifically, a telehealth visit is clinically appropriate because prescribing decisions rest on lab values (fasting glucose, HbA1c, liver function tests) and clinical history rather than a physical examination finding. "Type 2 diabetes management is well-suited to telemedicine delivery because treatment decisions are driven by laboratory data and symptom review," the American Diabetes Association's Standards of Care note in their 2024 update [6].

Patients in rural Missouri counties, where endocrinology access may require driving 60 or more miles, stand to benefit most from telehealth prescribing. HealthRX and similar telehealth platforms can prescribe pioglitazone and transmit the prescription electronically to any Missouri pharmacy, including mail-order pharmacies that ship directly to the patient's home.

Discount Programs and Savings Cards for Missouri Patients

Several programs can reduce pioglitazone costs below the already-low generic price, and Missouri patients qualify for all nationally available options. The most practical savings strategies depend on insurance status.

Uninsured or underinsured patients should start with free discount card programs. GoodRx, RxAssist, and NeedyMeds all index pioglitazone pricing at Missouri pharmacies and can push the effective price to $4 to $8 at participating locations. Walmart and Kroger (which operates Dillons in parts of Missouri) maintain $4 generic lists that include pioglitazone 15 mg and 30 mg tablets for a 30-day supply.

Patients with commercial insurance rarely need additional savings programs because Tier 1 copays are already low. If a plan charges more than $15 for generic pioglitazone, the patient may actually pay less by using a discount card and bypassing insurance, a strategy that is legal in Missouri and does not affect plan enrollment.

Medicare Part D enrollees cannot use manufacturer copay cards (federal anti-kickback statute prohibits it), but the $2,000 annual out-of-pocket cap under the Inflation Reduction Act means pioglitazone costs are capped regardless. The Extra Help (Low-Income Subsidy) program further reduces costs for qualifying beneficiaries, with copays as low as $1.55 for generic drugs in 2026 [7].

Takeda, the original manufacturer of Actos, discontinued its branded savings card program after patent expiration. No manufacturer copay card exists for brand-name Actos in 2026. Generic manufacturers do not typically offer patient savings programs because the drug is already priced below most copay thresholds.

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists pioglitazone at manufacturer cost plus a flat 15% margin and $5 dispensing fee, which often undercuts retail pharmacy pricing. Missouri patients can order through this mail-order pharmacy with a valid prescription.

Pioglitazone Pricing Compared with Other Missouri Diabetes Drugs

Pioglitazone is among the least expensive diabetes medications available in Missouri, and understanding where it sits relative to other agents helps patients and prescribers make cost-informed decisions.

Metformin remains the cheapest option at $4 to $8 per month for generic immediate-release tablets. Pioglitazone at $15 per month ranks second. Generic glipizide and glimepiride fall in the $4 to $12 range. After these older generics, costs escalate rapidly: generic empagliflozin (Jardiance) runs $40 to $80 per month, and GLP-1 receptor agonists like semaglutide (Ozempic) carry list prices exceeding $900 per month before insurance.

A 2023 cost-effectiveness analysis published in Diabetes Care found that adding pioglitazone to metformin as second-line therapy produced an incremental cost-effectiveness ratio of $8,200 per quality-adjusted life year (QALY) gained, well below the $50,000 threshold typically considered cost-effective in the United States [8]. That analysis did not account for pioglitazone's potential cardiovascular benefits demonstrated in the PROactive trial (N=5,238), where pioglitazone reduced the composite of all-cause mortality, non-fatal myocardial infarction, and stroke by 16% (HR 0.84 to 95% CI 0.72 to 0.98, P=0.027) in patients with type 2 diabetes and macrovascular disease [9].

For patients weighing pioglitazone against newer, more expensive agents, the price gap is worth noting. A year of pioglitazone costs approximately $180 at Missouri cash prices. A year of brand-name empagliflozin costs roughly $6,000 at list price. Both drugs improve glycemic control, but they work through different mechanisms and carry different risk-benefit profiles. Weight gain and fluid retention are pioglitazone's primary drawbacks, while empagliflozin offers cardiovascular and renal benefits demonstrated in the EMPA-REG OUTCOME trial [10].

Safety Monitoring Requirements That Affect Cost

Pioglitazone prescribing requires baseline and periodic liver function testing, which adds a small but real cost layer beyond the drug price itself. The FDA labeling recommends ALT measurement before initiation and periodically thereafter [2].

A basic hepatic function panel costs $15 to $50 at Missouri labs depending on insurance status. Quest Diagnostics and Labcorp, both with multiple Missouri draw sites, offer self-pay hepatic panels in the $20 to $30 range. Patients using telehealth services can order labs through direct-to-consumer lab platforms or have their telehealth provider send orders to a local lab.

The FDA also warns about pioglitazone's association with bladder cancer risk based on post-marketing surveillance data. A 10-year observational study (N=193,099) published in the BMJ found a modestly increased hazard ratio of 1.63 (95% CI 1.22 to 2.19) for bladder cancer with pioglitazone use exceeding 24 months [11]. This finding does not directly affect drug cost, but it influences prescriber willingness to use pioglitazone long-term, which in turn affects whether patients remain on this inexpensive option or transition to costlier alternatives.

Bone density monitoring is another consideration, particularly for postmenopausal women. The PROactive trial and subsequent analyses identified increased fracture risk with pioglitazone use, primarily in women [9]. A DEXA scan costs $100 to $250 in Missouri without insurance, though Medicare and most commercial plans cover screening DEXA scans for women over 65 and high-risk patients.

Total annual cost of pioglitazone therapy in Missouri, including the drug ($180), two hepatic panels ($40 to $60), and one HbA1c test ($20 to $40), runs approximately $240 to $280 for an uninsured patient paying cash at the lowest available prices.